Trial Profile
MITO-11: A Randomized Multicentre Phase II Trial With Pazopanib and Weekly Paclitaxel vs Weekly Paclitaxel in Platinum Resistant or Refractory Ovarian Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary) ; Paclitaxel
- Indications Ovarian cancer
- Focus Therapeutic Use
- Acronyms MITO - 11; MITO-11
- Sponsors GlaxoSmithKline
- 28 Oct 2015 Planned End Date changed from 1 Sep 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov.
- 08 Apr 2015 Planned End Date changed from 1 Sep 2014 to 1 Sep 2015, as reported by ClinicalTrials.gov.
- 03 Jun 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.